OPK logo

Opko Health Inc.

OPK

OPK: OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Opko's diagnostics business includes a core genetic testing operation. It has a development and commercial supply pharmaceutical company, as well as a global supply-chain operation and holding company in Ireland. Opko also owns a speciality active pharmaceutical ingredients manufacturer in Israel. The company's bio-reference testing business consists of routine testing and esoteric testing. Routine tests measure various health parameters, such as the functions of the heart, kidney, liver, thyroid, and other organs.

more

Show OPK Financials

Chart and Financial Data provided by TradingView

All
Government
Consumer Interest
SEC Filings
ESG/Other
Congress Trading

Recent trades of OPK by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by OPK's directors and management

Corporate Lobbying

Government lobbying spending instances

  • $25,000 Aug 04, 2023 Issue: Health Issues
  • $25,000 Apr 21, 2023 Issue: Health Issues
  • $50,000 Jan 08, 2023 Issue: Health Issues
  • $50,000 Nov 02, 2022 Issue: Health Issues
  • $50,000 Jul 07, 2022 Issue: Health Issues
  • $50,000 May 05, 2022 Issue: Health Issues
  • $50,000 Feb 09, 2022 Issue: Health Issues
  • $50,000 Nov 03, 2021 Issue: Health Issues
  • $50,000 Aug 05, 2021 Issue: Health Issues
  • $50,000 May 03, 2021 Issue: Health Issues
  • $50,000 Feb 03, 2021 Issue: Health Issues
  • $60,000 Nov 04, 2020 Issue: Health Issues
  • $50,000 Aug 05, 2020 Issue: Health Issues
  • $50,000 Apr 26, 2020 Issue: Health Issues
  • $50,000 Jan 23, 2020 Issue: Health Issues
  • $51,000 Nov 18, 2019 Issue: Health Issues
  • $37,000 Jul 30, 2019 Issue: Health Issues
  • $37,000 Jul 30, 2019 Issue: Health Issues
  • $25,000 Aug 17, 2016 Issue: Health Issues
  • $25,000 Jul 06, 2016 Issue: None
  • $36,000 Mar 31, 2015 Issue: Health Issues
  • $40,000 Jan 20, 2015 Issue: Health Issues Veterans Medicare/Medicaid
  • $45,000 Nov 16, 2014 Issue: Health Issues Veterans Government Issues
U.S. Patents

New patents grants

  • Patent Title: Hydrochloride salts of 8-[1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxymethyl]-8-phenyl-1,7-diazaspiro[4,5]decan-2-one and preparation process therefor Feb. 05, 2019
  • Patent Title: Process and intermediates for the synthesis of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds Jun. 19, 2018
  • Patent Title: Nk May. 15, 2018
  • Patent Title: Process and intermediates for the synthesis of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds Nov. 21, 2017
  • Patent Title: Nk Jun. 27, 2017
  • Patent Title: Nk Oct. 18, 2016
  • Patent Title: Pharmaceutical formulations: salts of 8-[1-3,5-bis-(trifluoromethyl)phenyl)-ethoxy-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same May. 24, 2016
  • Patent Title: Process and intermediates for the synthesis of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds Feb. 16, 2016
  • Patent Title: Process and intermediates for the synthesis of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds Feb. 02, 2016
  • Patent Title: Intravenous formulations of neurokinin-1 antagonists Aug. 11, 2015
  • Patent Title: Hypersulfated disaccharide formulations Apr. 14, 2015
  • Patent Title: Nk1 antagonists Aug. 05, 2014
  • Patent Title: Nk1 antagonists Jun. 17, 2014
  • Patent Title: Process and intermediates for the synthesis of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds Oct. 08, 2013
  • Patent Title: Hypersulfated disaccharide formulations Oct. 01, 2013
  • Patent Title: Hydrochloride salts of 8-[{1-(3,5-bis-trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor Jun. 25, 2013
  • Patent Title: Pharmaceutical formulations:salts of 8-[1-3,5-bis-(trifluoromethyl)phenyl)-ethoxymethyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same Mar. 26, 2013
  • Patent Title: Tablet formulations containing 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one salts and tablets made therefrom Jan. 29, 2013
  • Patent Title: Nk Sep. 25, 2012
  • Patent Title: Hydrochloride salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy)-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor May. 15, 2012
  • Patent Title: Nk Sep. 27, 2011
  • Patent Title: Pharmaceutical formulations: salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same Jul. 19, 2011
  • Patent Title: Nk Mar. 08, 2011
  • Patent Title: Nk1 antagonists May. 04, 2010
Government Contracts

Federal grants, loans, and purchases

WallStreetBets

Number of mentions of OPK in WallStreetBets Daily Discussion

OPK News

Recent insights relating to OPK

CNBC Recommendations

Recent picks made for OPK stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in OPK

Corporate Flights

Flights by private jets registered to OPK